Radiation boost added to groundbreaking cell therapy in fight against stubborn lymphoma
NCT ID NCT06043323
Summary
This study is testing whether combining a personalized cell therapy called axicabtagene ciloleucel (a type of CAR T-cell therapy) with radiation treatment is safe for adults with follicular lymphoma that has returned or hasn't responded to at least two prior treatments. Researchers want to see if adding radiation before the cell therapy helps control the cancer while managing serious side effects. The main goal is to measure safety by tracking severe reactions in the first month after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.